Endoscopic bariatric therapies

Barham K. Abu Dayyeh; Steven A. Edmundowicz; Sreenivasa Jonnalagadda; Nitin Kumar; Michael Larsen; Shelby Sullivan; Christopher C. Thompson; Subhas Banerjee

doi:10.1016/j.gie.2015.02.023

Endoscopic bariatric therapies

Barham K. Abu Dayyeh, Steven A. Edmundowicz, Sreenivasa Jonnalagadda, Nitin Kumar, Michael Larsen, Shelby Sullivan, Christopher C. Thompson, Subhas Banerjee

Gastroenterology and Hepatology

Research output: Contribution to journal › Article › peer-review

83 Scopus citations

Abstract

EBTs hold the promise of providing the next major breakthrough in the management of obesity. At a time when less than 1% of qualified patients actually undergo bariatric surgery, the development of a variety of new endoscopic therapies that replicate the physiological benefits of bariatric surgery in a safe, cost-effective, and minimally invasive fashion may potentially offer the best path to making a meaningful impact on the obesity epidemic. Currently investigated devices have established promising outcomes in short-term weight loss and in control of the metabolic and other medical adverse events of obesity. Pending regulatory approval in the United States, further studies will help define their optimal role in the comprehensive management of obesity.

Original language	English (US)
Pages (from-to)	1073-1086
Number of pages	14
Journal	Gastrointestinal endoscopy
Volume	81
Issue number	5
DOIs	https://doi.org/10.1016/j.gie.2015.02.023
State	Published - May 1 2015

ASJC Scopus subject areas

Gastroenterology
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.gie.2015.02.023

Cite this

@article{e45b4ed1f621410e967261982df62a14,

title = "Endoscopic bariatric therapies",

abstract = "EBTs hold the promise of providing the next major breakthrough in the management of obesity. At a time when less than 1% of qualified patients actually undergo bariatric surgery, the development of a variety of new endoscopic therapies that replicate the physiological benefits of bariatric surgery in a safe, cost-effective, and minimally invasive fashion may potentially offer the best path to making a meaningful impact on the obesity epidemic. Currently investigated devices have established promising outcomes in short-term weight loss and in control of the metabolic and other medical adverse events of obesity. Pending regulatory approval in the United States, further studies will help define their optimal role in the comprehensive management of obesity.",

author = "{Abu Dayyeh}, {Barham K.} and Edmundowicz, {Steven A.} and Sreenivasa Jonnalagadda and Nitin Kumar and Michael Larsen and Shelby Sullivan and Thompson, {Christopher C.} and Subhas Banerjee",

note = "Publisher Copyright: Copyright {\textcopyright} 2015 by the American Society for Gastrointestinal Endoscopy.",

year = "2015",

month = may,

day = "1",

doi = "10.1016/j.gie.2015.02.023",

language = "English (US)",

volume = "81",

pages = "1073--1086",

journal = "Gastrointestinal endoscopy",

issn = "0016-5107",

publisher = "Mosby Inc.",

number = "5",

}

TY - JOUR

T1 - Endoscopic bariatric therapies

AU - Abu Dayyeh, Barham K.

AU - Edmundowicz, Steven A.

AU - Jonnalagadda, Sreenivasa

AU - Kumar, Nitin

AU - Larsen, Michael

AU - Sullivan, Shelby

AU - Thompson, Christopher C.

AU - Banerjee, Subhas

PY - 2015/5/1

Y1 - 2015/5/1

N2 - EBTs hold the promise of providing the next major breakthrough in the management of obesity. At a time when less than 1% of qualified patients actually undergo bariatric surgery, the development of a variety of new endoscopic therapies that replicate the physiological benefits of bariatric surgery in a safe, cost-effective, and minimally invasive fashion may potentially offer the best path to making a meaningful impact on the obesity epidemic. Currently investigated devices have established promising outcomes in short-term weight loss and in control of the metabolic and other medical adverse events of obesity. Pending regulatory approval in the United States, further studies will help define their optimal role in the comprehensive management of obesity.

AB - EBTs hold the promise of providing the next major breakthrough in the management of obesity. At a time when less than 1% of qualified patients actually undergo bariatric surgery, the development of a variety of new endoscopic therapies that replicate the physiological benefits of bariatric surgery in a safe, cost-effective, and minimally invasive fashion may potentially offer the best path to making a meaningful impact on the obesity epidemic. Currently investigated devices have established promising outcomes in short-term weight loss and in control of the metabolic and other medical adverse events of obesity. Pending regulatory approval in the United States, further studies will help define their optimal role in the comprehensive management of obesity.

UR - http://www.scopus.com/inward/record.url?scp=84927570183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927570183&partnerID=8YFLogxK

U2 - 10.1016/j.gie.2015.02.023

DO - 10.1016/j.gie.2015.02.023

M3 - Article

C2 - 25828245

AN - SCOPUS:84927570183

SN - 0016-5107

VL - 81

SP - 1073

EP - 1086

JO - Gastrointestinal endoscopy

JF - Gastrointestinal endoscopy

IS - 5

ER -

Endoscopic bariatric therapies

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this